Analyst picks & changes

Biogen Inc.


Hancock Institutional analyst Robert Friedman initiated coverage with a "buy" and a one-year target of $50.

Beta interferon holds the key to the Cambridge, Mass., company's success as a fully integrated

Read the full 352 word article

How to gain access

Continue reading with a
two-week free trial.